Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Any patient with one of the following hematolymphoid malignancies or syndromes in whom allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease categories include:~  * Indolent advanced stage non-Hodgkin lymphomas~ * Mantle cell lymphoma~ * Chronic lymphocytic leukemia~ * Hodgkin disease (Hodgkin's lymphoma)~ * Acute leukemias in complete remission~ * Aplastic anemia~ * Paroxysmal nocturnal hemoglobinuria~ * Myelodysplastic or myeloproliferative syndromes.~ * Other selected malignancies/disorders may also be considered but must be approved by the transplant team and the Principal Investigator.~* Age \> 50 years, or if \< 50 years of age, considered to be at high risk for regimen-related toxicity associated with conventional myeloablative transplants due to pre-existing medical conditions or prior therapy.~* A fully human leukocyte antigen (HLA)-identical sibling or matched unrelated donor is available. Potential participants with one antigen mismatched donors can be considered but only after discussion with the transplant team and the Principal Investigator.~* Participant must be competent to give consent.~EXCLUSION CRITERIA:~* Progressive hematolymphoid malignancies despite conventional therapies, or acute leukemias not in complete remission.~* Uncontrolled central nervous system (CNS) involvement with disease~* Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment~* Pregnant~* Cardiac ejection fraction \< 30%~* Uncontrolled cardiac failure~* Pulmonary diffusing capacity (DLCO) \< 40% predicted~* Elevation of bilirubin to \> 3 mg/dL~* Transaminases \> 4 x the upper limit of normal~* Creatinine clearance \< 50 cc/min (24-hour urine collection)~* Karnofsky performance score \< 60%~* Poorly controlled hypertension on multiple antihypertensives~* Documented fungal disease that is progressive despite treatment~* HIV-positive. Other viral infections, ie, Hepatitis B- and C- positive, evaluated on a case-by-case basis~* Psychiatric disorders or psychosocial problems which in the opinion of the primary physician or Principal Investigator would place the patient at unacceptable risk from this regimen.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Non-myeloablative transplantation (Type: EXPERIMENTAL): Pre-transplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) infusion with Day 0 allogeneic hematopoietic cell transplant (HCT), followed by post-transplant immunosuppression by cyclosporine and mycophenolate mofetil.

Based on this trial design, predict the completion outcome and termination type (if applicable).